These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 25645838)

  • 1. Two mechanisms of killing of Pseudomonas aeruginosa by tobramycin assessed at multiple inocula via mechanism-based modeling.
    Bulitta JB; Ly NS; Landersdorfer CB; Wanigaratne NA; Velkov T; Yadav R; Oliver A; Martin L; Shin BS; Forrest A; Tsuji BT
    Antimicrob Agents Chemother; 2015 Apr; 59(4):2315-27. PubMed ID: 25645838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aminoglycoside Concentrations Required for Synergy with Carbapenems against Pseudomonas aeruginosa Determined via Mechanistic Studies and Modeling.
    Yadav R; Bulitta JB; Schneider EK; Shin BS; Velkov T; Nation RL; Landersdorfer CB
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28893782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of Synergistic Combination Regimens against Carbapenem- and Aminoglycoside-Resistant Clinical Pseudomonas aeruginosa Isolates via Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling.
    Yadav R; Bulitta JB; Nation RL; Landersdorfer CB
    Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27821448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel approach to optimize synergistic carbapenem-aminoglycoside combinations against carbapenem-resistant Acinetobacter baumannii.
    Yadav R; Landersdorfer CB; Nation RL; Boyce JD; Bulitta JB
    Antimicrob Agents Chemother; 2015 Apr; 59(4):2286-98. PubMed ID: 25645842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimization of a Meropenem-Tobramycin Combination Dosage Regimen against Hypermutable and Nonhypermutable Pseudomonas aeruginosa via Mechanism-Based Modeling and the Hollow-Fiber Infection Model.
    Landersdorfer CB; Rees VE; Yadav R; Rogers KE; Kim TH; Bergen PJ; Cheah SE; Boyce JD; Peleg AY; Oliver A; Shin BS; Nation RL; Bulitta JB
    Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29437610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance suppression by high-intensity, short-duration aminoglycoside exposure against hypermutable and non-hypermutable Pseudomonas aeruginosa.
    Rees VE; Bulitta JB; Oliver A; Tsuji BT; Rayner CR; Nation RL; Landersdorfer CB
    J Antimicrob Chemother; 2016 Nov; 71(11):3157-3167. PubMed ID: 27521357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimization and Evaluation of Piperacillin-Tobramycin Combination Dosage Regimens against Pseudomonas aeruginosa for Patients with Altered Pharmacokinetics via the Hollow-Fiber Infection Model and Mechanism-Based Modeling.
    Yadav R; Rogers KE; Bergen PJ; Bulitta JB; Kirkpatrick CMJ; Wallis SC; Paterson DL; Nation RL; Lipman J; Roberts JA; Landersdorfer CB
    Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29463528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinically relevant concentrations of fosfomycin combined with polymyxin B, tobramycin or ciprofloxacin enhance bacterial killing of Pseudomonas aeruginosa, but do not suppress the emergence of fosfomycin resistance.
    Walsh CC; Landersdorfer CB; McIntosh MP; Peleg AY; Hirsch EB; Kirkpatrick CM; Bergen PJ
    J Antimicrob Chemother; 2016 Aug; 71(8):2218-29. PubMed ID: 27118778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attenuation of colistin bactericidal activity by high inoculum of Pseudomonas aeruginosa characterized by a new mechanism-based population pharmacodynamic model.
    Bulitta JB; Yang JC; Yohonn L; Ly NS; Brown SV; D'Hondt RE; Jusko WJ; Forrest A; Tsuji BT
    Antimicrob Agents Chemother; 2010 May; 54(5):2051-62. PubMed ID: 20211900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Pharmacokinetic/Pharmacodynamic Model-Based Optimized Combination Regimens against Multidrug-Resistant Pseudomonas aeruginosa in a Murine Thigh Infection Model by Using Humanized Dosing Schemes.
    Yadav R; Bulitta JB; Wang J; Nation RL; Landersdorfer CB
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28993331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meropenem-Tobramycin Combination Regimens Combat Carbapenem-Resistant Pseudomonas aeruginosa in the Hollow-Fiber Infection Model Simulating Augmented Renal Clearance in Critically Ill Patients.
    Yadav R; Bergen PJ; Rogers KE; Kirkpatrick CMJ; Wallis SC; Huang Y; Bulitta JB; Paterson DL; Lipman J; Nation RL; Roberts JA; Landersdorfer CB
    Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31636062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adaptive resistance to aminoglycoside antibiotics in Pseudomonas aeruginosa.
    Gilleland LB; Gilleland HE; Gibson JA; Champlin FR
    J Med Microbiol; 1989 May; 29(1):41-50. PubMed ID: 2498520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel genetic determinants of low-level aminoglycoside resistance in Pseudomonas aeruginosa.
    Schurek KN; Marr AK; Taylor PK; Wiegand I; Semenec L; Khaira BK; Hancock RE
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4213-9. PubMed ID: 18824604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamics of intermittent- and continuous-infusion cefepime alone and in combination with once-daily tobramycin against Pseudomonas aeruginosa in an in vitro infection model.
    Tessier PR; Nicolau DP; Onyeji CO; Nightingale CH
    Chemotherapy; 1999; 45(4):284-95. PubMed ID: 10394012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aminoglycoside-resistance mechanisms for cystic fibrosis Pseudomonas aeruginosa isolates are unchanged by long-term, intermittent, inhaled tobramycin treatment.
    MacLeod DL; Nelson LE; Shawar RM; Lin BB; Lockwood LG; Dirk JE; Miller GH; Burns JL; Garber RL
    J Infect Dis; 2000 Mar; 181(3):1180-4. PubMed ID: 10720551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simulated Intravenous versus Inhaled Tobramycin with or without Intravenous Ceftazidime Evaluated against Hypermutable Pseudomonas aeruginosa via a Dynamic Biofilm Model and Mechanism-Based Modeling.
    Bilal H; Tait JR; Lang Y; Zhou J; Bergen PJ; Peleg AY; Bulitta JB; Oliver A; Nation RL; Landersdorfer CB
    Antimicrob Agents Chemother; 2022 Mar; 66(3):e0220321. PubMed ID: 35041509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The ionophore oxyclozanide enhances tobramycin killing of Pseudomonas aeruginosa biofilms by permeabilizing cells and depolarizing the membrane potential.
    Maiden MM; Zachos MP; Waters CM
    J Antimicrob Chemother; 2019 Apr; 74(4):894-906. PubMed ID: 30624737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergy between tobramycin and trivalent chromium ion in electrochemical control of Pseudomonas aeruginosa.
    Niepa TH; Wang H; Dabrowiak JC; Gilbert JL; Ren D
    Acta Biomater; 2016 May; 36():286-95. PubMed ID: 26996376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance emergence mechanism and mechanism of resistance suppression by tobramycin for cefepime for Pseudomonas aeruginosa.
    Drusano GL; Bonomo RA; Bahniuk N; Bulitta JB; Vanscoy B; Defiglio H; Fikes S; Brown D; Drawz SM; Kulawy R; Louie A
    Antimicrob Agents Chemother; 2012 Jan; 56(1):231-42. PubMed ID: 22005996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic killing of multidrug-resistant Pseudomonas aeruginosa at multiple inocula by colistin combined with doripenem in an in vitro pharmacokinetic/pharmacodynamic model.
    Bergen PJ; Tsuji BT; Bulitta JB; Forrest A; Jacob J; Sidjabat HE; Paterson DL; Nation RL; Li J
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5685-95. PubMed ID: 21911563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.